Sep 17, 2019
U.S. FDA Approves Supplemental New Drug Application (sNDA) for ERLEADA® (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Sep 11, 2019
New Head-to-Head Phase 3 Study Data Show Ponesimod Superiority Versus Aubagio® (teriflunomide) 14 mg in Adults with Relapsing Multiple Sclerosis (MS)
Sep 03, 2019
Janssen Announces U.S. FDA Breakthrough Therapy Designation for Investigational Prophylactic Vaccine for the Prevention of Respiratory Syncytial Virus in Older Adults
Aug 22, 2019
Janssen Reports Positive Top-line Phase 3 Study Results of Investigational, Long-acting Injectable HIV Treatment Regimen Administered Every Two Months
Jul 08, 2019
XARELTO® (rivaroxaban) Helps Protect Pediatric Patients from Blood Clots in Late-Breaking Phase 3 EINSTEIN-Jr Study
Jun 26, 2019
Tracleer (bosentan; Johnson & Johnson) Drug Overview & Product Profiles 2016-2025
Jun 14, 2019
Janssen reports top-line Phase 3 results for TREMFYA® (guselkumab) in adults with active psoriatic arthritis
Jun 03, 2019
Johnson & Johnson Celebrates Scientists Across Generations and Geographies with 2019 Dr. Paul Janssen Award for Biomedical Research and Champions of Science® Storytelling Challenge
Jun 03, 2019
IMBRUVICA® (ibrutinib) Long-Term Data from Two Pivotal Phase 3 Studies at ASCO and EHA Demonstrate Sustained Efficacy and Safety in Patients with Chronic Lymphocytic Leukemia (CLL)
May 31, 2019
ERLEADA® (apalutamide) Significantly Improved Overall Survival (OS) and Radiographic Progression-Free Survival (rPFS) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
May 22, 2019
U.S. FDA Grants Priority Review of INVOKANA® (canagliflozin) sNDA for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes
May 21, 2019
New Data Highlights the Value of SPRAVATO(TM) (esketamine) CIII Nasal Spray, the First New Antidepressant in Decades that Works Differently for Adults with Treatment-Resistant Depression (TRD)[1]
Apr 12, 2019
BALVERSA(TM) (erdafitinib) Receives U.S. FDA Approval for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma with Certain FGFR Genetic Alterations
Mar 07, 2019
Janssen Announces Results Of Two Phase 3 Studies Which Showed Long-Acting Injectable HIV Treatment Regimen Of Rilpivirine And Cabotegravir Demonstrated Comparable Safety And Efficacy To Daily Oral HIV Therapy
Mar 05, 2019
Janssen Announces U.S. FDA Approval of SPRAVATO(TM) (esketamine) CIII Nasal Spray for Adults with Treatment-Resistant Depression (TRD) Who Have Cycled Through Multiple Treatments Without Relief
Feb 14, 2019
Janssen Announces Preliminary Results from Phase 2 GALAHAD Study in Adults with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Pathway Defects (DRD)
Feb 12, 2019
U.S. FDA Approves DARZALEX® (daratumumab) Split-Dosing Regimen
Feb 04, 2019
First Atrial Fibrillation Patient Treated In Biosense Webster U.S. IDE Study Evaluating High Power, Short Duration Ablation Catheter
Jan 31, 2019
Janssen Enters Worldwide Collaboration and License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseases
Jan 28, 2019
U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia